Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating elevated cholesterol levels: the great Satan in perspective

M Gibaldi1, W Kradjan

  • 1School of Pharmacy, University of Washington, Seattle 98195, USA.

Journal of Clinical Pharmacology
|March 1, 1996
PubMed
Summary

High cholesterol is a risk factor for coronary heart disease (CHD). Current evidence supports cholesterol-lowering drugs for secondary prevention in patients with known CHD, but not for primary prevention in asymptomatic individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of plasma protein and tissue binding on the time course of drug concentration in plasma.

Journal of pharmacokinetics and biopharmaceutics·2010
Same author

The pharmacokinetics of penamecillin.

British journal of pharmacology and chemotherapy·2008
Same author

Vaccination updates.

The Western journal of medicine·2000
Same author

Are phytoestrogens a "natural alternative" to estrogen replacement therapy?

The Western journal of medicine·2000
Same author

Clinical clerkships for Japanese graduate pharmacy students in U.S. medical centers.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2000
Same author

Regulating angiogenesis: a new therapeutic strategy.

Journal of clinical pharmacology·1998

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Pharmacology

Background:

  • High cholesterol levels have been recognized as a significant risk factor for coronary heart disease (CHD).
  • Controversies exist regarding the efficacy and appropriate use of cholesterol-lowering drug therapy in both primary and secondary prevention strategies.

Purpose of the Study:

  • To review the historical developments linking high cholesterol to coronary heart disease.
  • To examine the ongoing debates surrounding the benefits of cholesterol-lowering medications for preventing cardiovascular events.
  • To evaluate the current evidence for using lipid-lowering drugs in patients with and without established coronary artery disease.

Main Methods:

  • This is a review article, synthesizing existing literature and clinical evidence.

Related Experiment Videos

  • Analysis of data regarding screening for high cholesterol and its role in primary prevention.
  • Evaluation of evidence supporting therapeutic interventions for secondary prevention in patients with diagnosed coronary heart disease.

    • Main Results:

    • Inadequate data currently supports widespread population screening for high cholesterol or primary prevention interventions in asymptomatic individuals.
    • There is substantial and growing evidence favoring aggressive lipid-lowering therapy for patients with established coronary heart disease (secondary prevention).
    • The benefit of primary prevention in specific patient subsets with defined risk factors requires further investigation.

    Conclusions:

    • Current evidence does not support routine cholesterol screening or primary prevention drug therapy for the general population or those with high cholesterol but no CHD.
    • Vigorous intervention with cholesterol-lowering drugs is strongly supported for patients with existing coronary heart disease.
    • Further research is necessary to identify specific patient groups who might benefit from primary prevention strategies.